Program Goals

Teriflunomide: Pooled Safety Data

Alemtuzumab: Thyroid Adverse Events

Alemtuzumab: Efficacy

Alfacalcidol (Vitamin D Analogue) for Managing MS-Related Fatigue

Thalamic Atrophy in RIS

Fingolimod and Brain Volume Change

Contraceptives and MS Susceptibility

Smoking and MS

Smoking and MS (cont)

MS Performance Testing

Driving Assessment

Cognitive Impairment in Pediatric Patients With MS

Pegylated Interferon: ADVANCE Study

Outcome Measures: Disease Worsening

Outcome Measures: Disease Worsening (cont)

Natalizumab: STRATA Study

Impact of Relapse Recovery on Progressive Disease

Risk Factors

Ofatumumab: MIRROR Study

Summary and Key Points

Abbreviations

References

References (cont)

References (cont)

References (cont)

References (cont)